Target Name: OR2M3
NCBI ID: G127062
Review Report on OR2M3 Target / Biomarker Content of Review Report on OR2M3 Target / Biomarker
OR2M3
Other Name(s): olfactory receptor OR1-54 | Novel 7 transmembrane receptor (rhodopsin family) protein | OR1-54 | Olfactory receptor, family 2, subfamily M, member 6 | Olfactory receptor family 2 subfamily M member 3 | Olfactory receptor 2M6 | OR2M3_HUMAN | OR2M3P | Olfactory receptor OR1-54 | Olfactory receptor 2M3 | olfactory receptor, family 2, subfamily M, member 6 | olfactory receptor, family 2, subfamily M, member 3 pseudogene | OR2M6 | olfactory receptor family 2 subfamily M member 3 | olfactory receptor 2M6 | Olfactory receptor, family 2, subfamily M, member 3 pseudogene | OST003 | novel 7 transmembrane receptor (rhodopsin family) protein

OR2M3: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States, it will account for over 21,000 deaths in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains relatively stagnant, with a five-year survival rate of only 29%. Therefore, there is a significant need for new and effective treatments.

One potential solution to this problem is the focus on targeting the olfactory receptor OR1-54. OR1-54 is a G protein-coupled receptor (GPCR) that is expressed in various tissues, including the breast, lung, and brain. It has been shown to play a role in cell signaling and has been implicated in various diseases, including cancer.

One of the promising aspects of OR1-54 is its potential as a drug target. By blocking the activity of OR1-54, researchers can inhibit the growth and spread of ovarian cancer cells. This has been shown to be an effective way to treat various types of cancer, including breast, ovarian, and brain cancer.

In addition to its potential as a drug target, OR1-54 has also been shown to be a potential biomarker for ovarian cancer. By measuring the levels of OR1-54 in cancer cells and patient samples, researchers can monitor the progress of the disease and the effectiveness of different treatments. This can be a valuable tool for researchers to develop new treatments and for clinicians to monitor patient outcomes.

OR1-54 has been shown to play a role in the development and progression of various types of cancer, including ovarian cancer. For example, studies have shown that OR1-54 is highly expressed in ovarian cancer cells and that inhibiting its activity can inhibit the growth of these cells. Additionally, overexpression of OR1-54 has been shown to promote the growth and progression of ovarian cancer.

In addition to its potential as a drug target and biomarker, OR1-54 also has potential as a diagnostic tool. By measuring the levels of OR1-54 in cancer cells and patient samples, researchers can monitor the progression of the disease and the effectiveness of different treatments. This can be a valuable tool for researchers to develop new treatments and for clinicians to monitor patient outcomes.

OR1-54 has also been shown to play a role in the regulation of various physiological processes, including cell signaling and inflammation. For example, studies have shown that OR1-54 is involved in the regulation of cell proliferation and that it can inhibit the growth of cancer cells. Additionally, OR1-54 has been shown to play a role in the regulation of inflammation and that it can reduce the inflammation that contributes to cancer progression.

In conclusion, OR1-54 is a promising drug target and biomarker for ovarian cancer. Its potential as a drug target has been shown by its ability to inhibit the growth and spread of ovarian cancer cells, as well as its potential as a biomarker for monitoring the progression of the disease. Its potential as a diagnostic tool is also an exciting area of research, as its ability to monitor the progression of the disease and the effectiveness of different treatments can be a valuable tool for researchers and clinicians alike. Further research is needed to fully understand the potential of OR1-54 as a drug target and biomarker for ovarian cancer.

Protein Name: Olfactory Receptor Family 2 Subfamily M Member 3

Functions: Odorant receptor

The "OR2M3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2M3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P